Clinical significance of regulatory T cells in patients with myelodysplastic syndrome

被引:28
作者
Hamdi, Wedad [1 ]
Ogawara, Hatsue [1 ]
Handa, Hiroshi [1 ]
Tsukamoto, Norifumi [2 ]
Nojima, Yoshihisa [2 ]
Murakami, Hirokazu [1 ]
机构
[1] Gunma Univ, Sch Hlth Sci, Dept Lab Sci, Gunma 3718514, Japan
[2] Gunma Univ, Grad Sch Med, Gunma 3718514, Japan
关键词
myelodysplastic syndrome; Foxp3; regulatory T cells; CD8; ratio; Th1; Th2; RATIO; LYMPHOCYTES; FREQUENCY; LYMPHOMA; CANCER;
D O I
10.1111/j.1600-0609.2008.01182.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Foxp3(+) regulatory T cells (Tregs) play a central role in maintaining immune tolerance. Their expansion in malignant diseases leads to the suppression of host anti-tumour responses. In this study, we evaluated the clinical significance of Tregs in patients with myelodysplastic syndrome (MDS). We analysed the number of CD4(+) CD25(+) Foxp3(+) Tregs using three-colour flow cytometry in the peripheral blood of 26 patients with MDS classified according to the World Health Organization classification method into four cases of refractory anaemia and refractory anaemia with ringed sideroblasts (RA/RARS), 15 cases of refractory cytopenia with multilineage dysplasia (RCMD), three cases of refractory anaemia with excess blast-1 (RAEB-1) and four cases of refractory anaemia with excess blast-2 (RAEB-2). Eighteen healthy volunteers were included as the control group. The mean absolute numbers of Tregs in the RA/RARS group (0.06 x 10(9)/L; 95% CI, 0.02-0.10 x 10(9)/L) and RAEB group (0.06 x 10(9)/L; 95% CI, 0.02-0.10 x 10(9)/L) were significantly higher than that of the control group (0.03 x 10(9)/L; 95% CI, 0.02-0.03 x 10(9)/L) (P < 0.05). However, in the RCMD group, there was no significant difference in the mean absolute number of Tregs (0.03 x 10(9)/L; 95% CI, 0.02-0.04 x 10(9)/L) compared with the control group. Regarding the mean level of the CD8/Foxp3 ratio, there were significant decreases in the RA/RARS group (2.8; 95% CI, 0.7-4.9; P < 0.01), RCMD group (3.4; 95% CI, 2.0-4.4; P < 0.001) and RAEB group (2.1; 95% CI, 1.7-2.5; P < 0.001) compared with the control group (6.1; 95% CI, 5.1-7.0). The expansion of natural CD4(+) Tregs may contribute to the suppression of CD8 through the Th1-mediated immune response in MDS. The low CD8/Foxp3 ratio is a characteristic feature in MDS. To determine whether the expansion of CD4(+) Tregs contributes to the progression of MDS subtypes into more aggressive subtypes, more MDS cases and further follow-up are required.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 26 条
[1]  
Barrett J, 2000, SEMIN HEMATOL, V37, P15
[2]   IMMUNOREGULATORY ABNORMALITIES IN MYELODYSPLASTIC DISORDERS [J].
BAUMANN, MA ;
MILSON, TJ ;
PATRICK, CW ;
LIBNOCH, JA ;
KELLER, RH .
AMERICAN JOURNAL OF HEMATOLOGY, 1986, 22 (01) :17-26
[3]   Natural regulatory T cells in infectious disease [J].
Belkaid, Y ;
Rouse, BT .
NATURE IMMUNOLOGY, 2005, 6 (04) :353-360
[4]   Natural versus adaptive regulatory T cells [J].
Bluestone, JA ;
Abbas, AK .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (03) :253-257
[5]   Are regulatory T-cells linked with aging? [J].
Dejaco, Christian ;
Duftner, Christina ;
Schirmer, Michael .
EXPERIMENTAL GERONTOLOGY, 2006, 41 (04) :339-345
[6]   A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 [J].
Fontenot, JD ;
Rudensky, AY .
NATURE IMMUNOLOGY, 2005, 6 (04) :331-337
[7]   The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age [J].
Gregg, R ;
Smith, CM ;
Clark, FJ ;
Dunnion, D ;
Khan, N ;
Chakraverty, R ;
Nayak, L ;
Moss, PA .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 140 (03) :540-546
[8]  
HAMDI W, INT J CLIN IN PRESS
[9]   Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio:: Which variable determines survival of cervical cancer patients? [J].
Jordanova, Ekaterina S. ;
Gorter, Arko ;
Ayachi, Ouissarn ;
Prins, Frans ;
Durrant, Lindy G. ;
Kenter, Gerrima G. ;
van der Burg, Sjoerd H. ;
Fleuren, Gert Jan .
CLINICAL CANCER RESEARCH, 2008, 14 (07) :2028-2035
[10]   A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia [J].
Killick, SB ;
Mufti, G ;
Cavenagh, JD ;
Mijovic, A ;
Peacock, JL ;
Gordon-Smith, EC ;
Bowen, DT ;
Marsh, JCW .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (04) :679-684